Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

2.835
+0.0200.71%
Volume:5.85M
Turnover:16.17M
Market Cap:1.74B
PE:195.55
High:2.845
Open:2.825
Low:2.665
Close:2.815
52wk High:15.960
52wk Low:2.665
Shares:615.00M
HK Float Shares:615.00M
Volume Ratio:1.02
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.014
ROE:-4.11%
ROA:-1.28%
PB:0.56
PE(LYR):195.56
PS:2.39

Loading ...

Shandong Boan Biotechnology Co - Purchase Price for Leased Assets is Rmb75.00 Mln

THOMSON REUTERS
·
Aug 27

Shandong Boan Biotechnology Co Ltd - Industrial Bank Financial Leasing Will Purchase Leased Assets from Co

THOMSON REUTERS
·
Aug 27

Shandong Boan Biotech Enters RMB 75 Million Sale-and-Leaseback Deal with Industrial Bank Financial Leasing

Reuters
·
Aug 27

Shandong Boan Biotech Swings to FY26 H1 Net Loss of RMB 83.01 Million; Revenue Drops 40.8% to RMB 233 Million

Reuters
·
Aug 27

Boan Biotech Secures CDE IND Nod for First-in-Class TL1A/IL-23 Bispecific Antibody BA2201 to Treat IBD

Bulletin Express
·
Aug 26

BOAN BIOTECH (06955) Submits IND for BA2201 (TL1A/IL-23) as CDE Accepts Clinical Trial Application

Stock News
·
Aug 26

Shandong Boan Biotech Says China CDE Accepts IND Filing for Ba2201 Bispecific Antibody

Reuters
·
Aug 26

Shandong Boan Biotechnology Co Ltd - Cde Acceptance of Ind Application for Tl1a/Il-23 Bispecific Antibody Ba2201

THOMSON REUTERS
·
Aug 26

Bioan Biotech's BA1302 (CD228 ADC) Completes China Phase Ia Clinical Study

Stock News
·
Aug 14

BOAN Biotech Schedules 27 Aug 2026 Board Meeting to Approve 1H26 Results and Assess Interim Dividend

Bulletin Express
·
Aug 14

BOAN BIOTECH (06955) Warns of Loss, Expects Net Loss Attributable to Shareholders of Approximately RMB 79 Million to RMB 89 Million for the First Half of the Year, a Swing from Profit to Loss

Stock News
·
Aug 14

Shandong Boan Biotechnology Expects Net Loss Attributable of RMB79 Million-RMB89 Million

Reuters
·
Aug 14

Shandong Boan Biotech Completes China Phase Ia Trial of Ba1302 CD228-Targeted ADC

Reuters
·
Aug 14

Shandong Boan Biotechnology Co - Expected Turnaround to Loss Mainly Due to Increased R&D Expenditure in Hy

THOMSON REUTERS
·
Aug 14

Shandong Boan Biotech Schedules Board Meeting on Interim Results, Dividend Review

Reuters
·
Aug 14

Hong Kong Stock Movers: BOAN BIOTECH Surges Over 3% Before Noon as Aflibercept Injection Seeks Brazilian Approval

Stock News
·
Aug 11

BOAN BIOTECH Affirms Stable 622.33 Million Share Base and Meets Public-Float Waiver in July 2026 Return

Bulletin Express
·
Aug 06

Shandong Boan Biotechnology Submits BLA for Ba9101 to Anvisa in Brazil

Reuters
·
Aug 05

Shandong Boan Files Brazil Marketing Application for Ba9101 Aflibercept Biosimilar with Anvisa

Reuters
·
Aug 05

Shandong Boan Biotechnology Co - Submits Bla for Ba9101 to Anvisa in Brazil

THOMSON REUTERS
·
Aug 05